Abstract The World Health Organization recommends establishing that human
papillomavirus vaccination is cost-effective before vaccine introduction. We searched …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Abstract Background The World Health Organization (WHO) recommends that the cost
effectiveness of introducing human papillomavirus (HPV) vaccination is considered before …

Fifteen years following the approval of the first human papillomavirus (HPV) vaccine,
cervical cancer continues to be a significant source of morbidity and mortality among women …

The recent approval of human papillomavirus (HPV) vaccine means that decision makers
need information beyond that available from randomized clinical trials to recommend …

Cost-effectiveness analysis (CEA) is a well-known, but resource intensive, method for
comparing the costs and health outcomes of health interventions. To build on available …

Please cite this paper as: Sharma M, Ortendahl J, van der Ham E, Sy S, Kim J. Cost‐
effectiveness of human papillomavirus vaccination and cervical cancer screening in …

Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Background The success of human papillomavirus (HPV) national immunization program
depends on effective strategies in optimizing the uptake of HPV vaccine. Given the …

Abstract Background and Objectives Giving the human papillomavirus (HPV) vaccination to
females has been shown to be cost-effective in most countries. The epidemiological …